Emyria Receives Ethics Approval for MDMA-assisted Therapy
Released
Released
Announcement PDF
ASX Announcement
08 Jun 2023 ASX Announcement
07 Mar 2023
Emyria receives ethics approval for
MDMA-assisted therapy
HIGHLIGHTS
Emyria receives Human Research Ethics Committee (HREC) approval to commence a
pivotal MDMA-assisted therapy trial (EMDMA-001) for Post-Traumatic Stress Disorder with
partners, the PAX Centre
PAX Centre is one of Australia’s leading trauma-focused, multidisciplinary psychiatric
services specialising in the treatment of complex trauma 1
Emyria’s MDMA-assisted therapy trial will support the development of:
●
Best-practice protocols for safe, community-based delivery of MDMA-assisted therapy
●
Authorised Prescriber applications for Emyria-network psychiatrists from July 1st
●
Cost effectiveness evaluations to support payer engagement and commercialisation
●
Real World Data collection methods to support safety and care model improvement
Therapist training is completed for 20 psychiatrists, GPs, mental health nurses, clinical
psychologists and counsellors by renowned psychiatrist and psychedelic-assisted therapy
researcher, Dr. Ben Sessa 2
Pharmaceutical-grade MDMA has been secured 3 ; Importation process has commenced
Emyria will now develop care models for psilocybin-assisted therapy
Emyria Limited (ASX: EMD), a clinical stage biotech and medical services provider (Emyria
or the Company), is pleased to announce is has received Human Research Ethics Committee
approval to conduct its proposed twelve-month, open-label, single centre MDMA-assisted
therapy clinical trial (EMDMA-001) for patients with Post-Traumatic Stress Disorder (PTSD).
PTSD is a significant mental health issue in both the United States and Australia. In the
US, approximately 10 million people are estimated to suffer from PTSD with total excess
economic burden costs estimated to be around $232.2 billion per year. 4
In Australia, approximately 1 million people suffer from PTSD. 30-50% of patients have an
ineffective response or resistance to standard therapies. There is an increasing urgent need
for more effective therapies. 5
MDMA-assisted therapy has shown promising results for patients with PTSD 6,
Until the TGA announcement its use has been limited to research settings requiring
extensive restrictive protocols limiting its use to trial patients.
Emyria ASX Announcement | 08 Jun 2023
1
Emyria’s Managing Director, Dr Michael Winlo said: We're excited to announce the recent ethics
approval for Emyria’s MDMA-assisted therapy trial for PTSD. This pivotal step, made possible by our
partnership with The Pax Centre, highlights our commitment to advancing new psychiatric care.
Our joint endeavor aims to deliver a safe, cost-effective, and scientifically grounded approach to
PTSD treatment that can support the development of cost-effective and scalable MDMA-assisted
therapy delivery in the community.
This trial is expected to improve patient outcomes in a safe environment and generate valuable
Real World Data, allowing program improvements and furthering Emyria’s drug analogue
development. For our investors and shareholders, this represents a significant milestone and
growth opportunity in the burgeoning field of psychedelic-assisted therapy.”
Starting from July 1st, 2023, the TGA has changed the classification that will enable patient
access to MDMA-assisted therapy as a Schedule 8 controlled medicine 7 . This is via prescription
from specialist psychiatrists who have obtained “Authorised Prescriber” status. The Royal
Australian and New Zealand College of Psychiatrists have required that, “prescribing
psychiatrists must demonstrate adequate training, evidence-based treatment protocols,
patient selection, and monitoring to be approved to prescribe this therapy. Ongoing
psychotherapeutic support is also essential for this treatment model.” 8
It is anticipated that only a small number of psychiatrists with first-hand experience working
with psychedelic-assisted therapies in clinical trials will meet the requirements for Authorised
Prescriber status.
Emyria’s licensable package, combining a robust, ethics-approved care model and reliable
drug supply, 3 has been developed to support Authorised Prescriber (AP) applications from
Emyria-network psychiatrists from July 1st. It is anticipated that “Emyria-network APs”
supported by a trained, multidisciplinary team, will be some of the first specialists able to offer
psychedelic-assisted therapy as a commercially viable service for suitably screened patients.
To support this vision, Emyria draws upon extensive experience in prescribing unregistered
treatments at Emerald Clinics, care model design and Real World Data capture. By applying
Emyria’s well-established, data driven approach to the emerging field of psychedelic-assisted
therapies, the Company believes it can help its healthcare provider partners enhance their
service offering and improve the lives of Australian patients diagnosed with PTSD and
treatment-resistant depression.
Emyria sees the establishment of a comprehensive and multidisciplinary provider network as a
commercially viable pathway to further its mission. By fostering a mutually beneficial
ecosystem, Emyria is extending its clinical offerings and facilitating safe patient access to
innovative treatments. The proprietary Real-World Data gathered also underpins the Company’s
novel drug development programs.
The clinical data generated in this trial will support ongoing care model improvements, crucial
cost-effectiveness studies to support reimbursement, and also Emyria’s active MDMA-inspired
drug development program with partner the University of Western Australia.
Emyria ASX Announcement | 08 Jun 2023
2
Emyria’s novel, MDMA-inspired drug discovery program is seeking to create new medicines.
Current, leading programs are focussed on:
● Faster acting MDMA-like compounds with the potential to shorten treatment session
times and increase the number of patients treated and;
● A novel therapy to ameliorate the symptoms of Parkinson’s disease treatment.
The recent rescheduling of MDMA by the TGA further supports Emyria’s novel
MDMA-inspired drug development program by opening a pathway to registration and
reimbursement for these novel compounds across a range of neuropsychiatric disorders.
Emyria is advancing its drug discovery program in Australia and the United States to
identify novel, MDMA-like compounds with therapeutic potential, while collaborating with local
clinical partners to improve patient access and ongoing research.
RECENT TRACTION & UPCOMING MILESTONES
CLINICAL PROGRAMS
“Direct-To-Consumer”
Formulation
optimisation (RX5)
Phase 1 study done
Phase 3
commencement
Regulatory submission
Commercial strategy
Australia
PRE-CLINICAL + THERAPY PROGRAMS
“Prescription Medicine”
New Drug Discovery
Psychedelic-Assisted Therapy
Formulation optimisation
(RX7 > RX9)
Continuous creation
& screening
Protocols developed
(MDMA)
Preclinical Screening
Program for Pain
First patent family filed
Clinical partnerships
US-focused
preclinical program
Real-World Data system
Metabolic studies
MDMA supply secured
Lead selection
Therapist training
Phase 1 trials
Ethics approval (MDMA)
Global commercial strategy
Protocol developed (psilocybin)
Phase 1
Pre-IND (FDA)
Pivotal trials
Commercial strategy Europe
Commercial strategy USA
Psilocybin supply secured
This release has been approved by the Board of Emyria.
FOR FURTHER INFORMATION
Dr. Michael Winlo Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
1.
2.
3.
4.
5.
6.
7.
8.
Sufian
Ahmad
Corporate
+61 (0) 412 316 162
info@62capital.com.au
Advisor
https://www.paxcentre.com.au/our-story
http://www.drsessa.com/specialist-psychopharmacology-research/
See ASX release 13 Feb 2023
Davis LL, Schein J, Cloutier M, et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective.
J Clin Psychiatry. 2022;83(3):21m14116
https://www.phoenixaustralia.org/
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled
phase 3 study. Nat Med 27, 1025–1033 (2021)
https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-current-poisons-standard-june-20
22-acms-38-psilocybine-and-mdma.pdf accessed 05 Feb 2023
https://www.ranzcp.org/news-policy/news/change-to-classification-of-psilocybin-and-mdma
Emyria ASX Announcement | 08 Jun 2023
3
ABOUT EMYRIA | emyria.com
Emyria Limited is a clinical drug development and care delivery company focused on accelerating
drug development and improving patient outcomes in neuroscience and mental health via:
●
Drug Development: Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for
registration against multiple indications. Emyria’s first dose form, EMD-RX5, is in Phase 3 trials.
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest
libraries of MDMA-like compounds with partner, the University of Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers robust and ethically-sourced data with
patients cared for at Emyria’s own specialist clinical service (Emerald Clinics) and partners.
Emyria RWD can help support drug development and care model improvement.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking
questions and comments, which our team can respond to where possible.
ABOUT PAX Centre | paxcentre.com.au
The Pax Centre (‘PAX’) provides expert assessment and treatment for those suffering from the
psychological impact of traumatic life experiences.
PAX offers an individualised approach to assessing and treating people suffering from the effects of
traumatic life experiences. Such experiences can result in various mental health problems including
post-traumatic stress disorder (PTSD), complex PTSD and dissociation, depression, other anxiety
disorders, chronic adjustment reactions, somatic syndromes and abuse of alcohol or drugs.
Traumatic experiences can include a wide range of life events, such as physical or sexual assault,
natural disasters, medical procedures, sudden bereavements or wartime incidents. Whilst most
people can, and do, recover from such experiences with the support of family and friends, some will
develop significant problems which can have a major effect on their day-to-day lives, often affecting
their work and relationships.
Complex trauma differs from single-incident trauma in that it is a multifaceted syndrome where the
traumatic event(s) were relational, repeated, and cumulative; and it usually occurs at developmentally
sensitive stages of neurological maturation. For this reason, the social, emotional, behavioural and
interpersonal effects of childhood trauma are often pervasive and continue to affect many different
areas of people’s adult lives long after the original trauma has passed and/or been debriefed. PAX
have found that when these situations arise, an early assessment, diagnosis and the initiation of
appropriate evidence-based treatment strategies is vital.
In addition to this, PAX teach proactive, preventative and health expanding strategies to enable the
personal growth, improved well-being and performance of our clients. Empowering PAX clients
through the acquisition of new skills and tools is the focus of our philosophy.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future
expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may
differ materially from those indicated by such forward-looking statements as a result of various important factors, including:
the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements
included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent
events and developments will cause the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the
date hereof.
Emyria ASX Announcement | 08 Jun 2023
4
Share your feedback
Discover